Scalper1 News
Big-cap biotech Biogen (BIIB) missed Wall Street’s Q1 estimates Friday as its multiple-sclerosis drug Tecfidera ran into unexpected headwinds, sending its stock down to a two-month low in early trading. Biogen’s earnings excluding one-time items rose 55% over the year-earlier quarter to $3.82 a share, 9 cents short of analysts’ consensus. Sales rose 20% to $2.6 billion, about $100 million below the Street’s average estimate. The shortfall was Scalper1 News
Scalper1 News